Tagged with Disease

Hungary Dr. Péter Ofner, Former Director of the Gottsegen Hungarian Insititute of Cardiology, shares his insights on the cardiological capabilities of the institute, the epidemiological profile of the country, the collaborations with industry players, and outlooks for the future of this field as well as the country.   Hungary is a…

Puerto Rico Based in Tampa, Florida, Romark is a research-based pharmaceutical company focused on developing innovative treatments for infectious diseases. The company recently inaugurated its first finished products manufacturing facilities in Puerto Rico, transforming itself into a vertically integrated organization. CEO Marc Ayers extols the strengths of Puerto Rico as manufacturing location…

UAE The UAE ranks as a world leader in rapid drug approvals with its fast-track registration system that accelerates the process and eliminates long waiting times for innovative and orphan drugs.   If you bring innovation, the [UAE] government will support you on all levels Georg Schroeckenfuchs, Novartis In January 2018…

UAE Dr Omar Hallak, head of the cardiovascular department at King’s College Hospital Dubai (KCHD) and president of the Gulf chapter of the International Society of Endovascular Specialists, discusses issues pertaining to cardiovascular disease (CVD) within the UAE, 4TS – a conference founded by Hallak to encourage the sharing of knowledge…

UAE LIFEPharma, a subsidiary of UAE-based VPS Healthcare, has signed a Dh 200 million (USD 55 million) deal with Canada’s Apotex to produce 120 million generic tablets and medicines for Motor Neurone Disease annually over the next 10 years.   This partnership is an important milestone, not only for LIFEPharma and…

Sweden Infectious diseases kill over 17 million people each year, according to the WHO, which is why vaccine-specialist Valneva is continuing to grow and develop the next generation of vaccines. Janet Hoogstraate, chair of the Management Board of Valneva Sweden, explains the high-quality of their manufacturing operations in the country and…

China Eric Bouteiller outlines the paradigm shift occurring in China around rare diseases and how the country has the potential to lead the global pharmaceutical industry in this vital area.   Through exchanges with public officials, academics, representatives of patient associations and industry experts, we sensed a paradigm shift The 8th…

Taiwan United Biomedical, Inc. (UBI) is dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases and is passionate about delivering science-driven innovation with platform capabilities. Chang Yi Wang is the Chairperson and CSO of United BioPharma (UBP), a member of the UBI group of…

Sweden Grifols is a pioneer in plasma science that develops plasma into essential medicines used to treat rare, chronic and life-threatening conditions. Eric Björnestål, general manager for the Nordic region, explains how the company is leveraging its knowledge of the public tender process to continue to grow in the region, highlights…

Sweden Olav Fromm, managing director of Chiesi Nordics, explains the deep roots of Chiesi in Sweden, where its blockbuster drug, a surfactant for treating neonatal babies, was developed. He also touches upon the strategic importance of the region to Chiesi, with the recent creation of a fully-fledged Nordic subsidiary, which will…

Sweden Johan Wäborg, General Manager Nordic countries at Actelion, shares the importance of Sweden for the group due to its world-class healthcare system and community of experts as well as its national quality and health registries which make the country an ideal environment for early launches and follow-up of treatment outcomes.…

Spain Though still one of the younger and lesser-known outfits inhabiting the European drug development landscape, Irish-headquartered rare disease specialist, Jazz pharma has been making tremendous headway in the onco-haematology and sleep disorder spaces and the Spanish affiliate is absolutely no exception.   We blend the lessons of art with our…